Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q1 FY2010 Earnings Presentation
15 slides from Daiichi Sankyo's earnings presentation, Jul 30, 2010
Slide 1: Results for Q1 FY2010
Results for Q1 FY2010 (April 1 - June 30, 2010) July 30, 2010
Slide 2: Results Overview
Results Overview
Slide 3: Overview of FY2010 Q1 Results
Overview of FY2010 Q1 Results (Billions of yen) Sales (Billions of yen) Operating Income 300.0 256.4 227.1 61.1 50.0 200.0 26.8 25.0 100.0 0.0 0.0 FY2009 Q1 FY2010 Q1 FY2009 Q1 FY2010 Q1 (Billions of yen) Ordinary Income (Billions of yen) Net Income 75.0 30.0 70.1 20.0 50.0 33.1 7.2 10.0 25.0 0.0 -6
Slide 4: Overview of FY2010 Q1 Results - compared with FY2009 Q1 results
Overview of FY2010 Q1 Results - compared with FY2009 Q1 results - (Billions of yen, ratio to sales) FY2009 FY2010 FY2009 Q1 FY2010 Q1 Q1Results Q1 Results YoY Ranbaxy Ranbaxy YoY (2)-(1) Jan-Mar Results Jan-Mar Results (4)-(3) (1) (2) (3) (4) 100% 100% 100% 100% Net Sales 227.1 256.4 29.3 29.7 54.9
Slide 5: Year on Year Comparisons
Year on Year Comparisons 1. Net Sales ¥256.4 billion (+¥29.3 billion, +12.9%) Positive factors: ● Valacyclovir and other products from Ranbaxy (+¥25.1 billion) ● Olmesartan (+¥4.2 billion) ● Loxonin (+¥1.8 billion) ● Milestone payment received on the approval of Denosumab in the European Union N
Slide 6: Year on Year Comparisons
Year on Year Comparisons 3. Ordinary Income ¥70.1 billion (+¥62.9 billion, +877.7%) Non-operating income (+¥7.9 billion) ● Ranbaxy-related (+¥9.1 billion) Gain on valuation of derivatives and forex gains etc. Non-operating expenses (-¥20.7 billion) ● Ranbaxy-related (-¥21.6 billion) Loss in prev
Slide 7: Overview of FY2010 Forecast
Overview of FY2010 Forecast (Billions of yen, ratio to sales) FY2010 Forecast 1st half Forecast Full year Q1 Forecast Results Progress (2) (1) (1)/(2) 100.0% 100.0% 100.0% Net Sales 256.4 26.2% 490.0 980.0 25.0% 29.4% 29.6% Cost of Sales 64.1 22.1% 144.0 290.0 SG&A 34.2% 39.6% 39.8% expenses 87.7 22
Slide 8: FY2010 Forecast
FY2010 Forecast No revision to forecast at this stage z We have reflected Ranbaxy’s Q1 results (Jan-Mar 2010) in our consolidated forecast so far, and would need to carefully examine Ranbaxy’s business performance after Q2 to determine the impact of potential revision in our overall forecast. z Afte
Slide 9: Sales of Major Products
Sales of Major Products (Billions of yen) FY2010 Forecast Q1 Full Year Results Progress Comparison Forecast Comparison (1) (1)/(2) with FY09 Q1 (2) with FY09 Olmesartan antihypertensive 60.2 23.2% 4.2 260.0 21.7 GLOBAL Levofloxacin synthetic antibacterial agent 17.0 24.2% -2.8 70.0 -17.2 Pravastatin
Slide 10: Sales of Major Products (Local Currency Basis)
Sales of Major Products (Local Currency Basis) FY2010 Forecast Full Year Q1 Results (1) Progress YoY YoY (2) (1)/(2) Change Change Benicar/Benicar HCT 233 23.4% 6 994 37 Daiichi Sankyo, Inc. <US> Azor 42 28.8% 10 144 7 (Mil $) Welchol 76 24.1% 5 317 20 Daiichi Sankyo Europe GmbH Olmetec/Olmetec Plus
Slide 11: R&D Pipeline Update
R&D Pipeline Update
Slide 12: R&D Pipeline Progress
R&D Pipeline Progress Progress from May 2010 z Loxoprofen sodium hydrate / Gel (Japan) Anti-inflammatory and analgesic Application Æ Approval z CS-8635 (US): US Trade Name : TRIBENZORTM Three-in-One Combination Product (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) Application Æ Approval z
Slide 13: Development Pipeline
Development Pipeline Phase 1 Phase 2 Phase 3 Application - Prasugrel (ACS-MM) - Edoxaban (JPN) Cardiovascular diseases - DB-772d - Edoxaban(AF/VTE) - CS-8635(EU) Diabetes mellitus -CS-1036 - Tigatuzumab - Nimotuzumab (#) Malignant neoplasm - U3-1287 - ARQ 197 - CS-7017 -CS-4771 - Levofloxacin inj (J
Slide 14: FY2010 Daiichi Sankyo Briefings
FY2010 Daiichi Sankyo Briefings Date (JST) Ranbaxy August 12, 2010 2010 Q2 Financial Results FY2010 Q2 Financial Results October 29, 2010 FY2010 2Q Financial Results November 1, 2010 Meeting (14:00 Media Relations / 16:30 Investors Relations) R&D Meeting December, 2010 FY2010 Q3 Financial Results Ja
Slide 15: Contact address regarding this material
Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: +81-3-6225-1126 Public Relations +81-3-6225-1125 Investor Relations FAX: +81-3-6225-1132 Each numerical value regarding the future prospect in this material is derived from our judgment and assu
Daiichi Sankyo Company — Q1 FY2010 Earnings Presentation on 6ix